Background. Drug-resistant tuberculosis poses a growing challenge to global public health. However, the diversity and dynamics of the bacterial population during acquisition of drug resistance have yet to be carefully examined.
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Background. Drug-resistant tuberculosis poses a growing challenge to global public health. However, the diversity and dynamics of the bacterial population during acquisition of drug resistance have yet to be carefully examined.
Methods. Whole-genome sequencing was performed on 7 serial Mycobacterium tuberculosis (M. tuberculosis) populations from 3 patients during different stages in the development of drug resistance. The population diversity was assessed by the number and frequencies of unfixed mutations in each sample.
Results. For each bacterial population, 8-41 unfixed mutations were monitored by the fraction of single-nucleotide polymorphisms at specific loci. Among them, as many as 4 to 5 resistance-conferring mutations were transiently detected in the same single sputum, but ultimately only a single type of mutant was fixed. In addition, we identified 14 potential compensatory mutations that occurred during or after the emergence of resistance-conferring mutations.
Conclusions. M. tuberculosis population within patients exhibited considerable genetic diversity, which underwent selections for most fit resistant mutant. These findings have important implications and emphasize the need for early diagnosis of tuberculosis to decrease the chance of evolving highly fit drug-resistant strains.
Drug-resistant tuberculosis, especially multidrug resistant (MDR) and extensively drug-resistant tuberculosis (XDR-Tuberculosis) is a growing challenge to global tuberculosis control. Mycobacterium tuberculosis (M. tuberculosis) acquires antibiotic resistance mainly through chromosomal mutations that either directly affect the binding site of the drug or mutate bacterial enzymes involved in activating a pro-drug [1] . Such mutations often confer fitness defect on the resulting drug-resistant progeny. However, although hundreds of resistance-associated mutations have been identified in vitro and in vivo [2] , drug-resistant alleles in clinical isolates are characterized by the prevalence of low-or no-cost mutations [3] [4] [5] , suggesting that selection for drug-resistant alleles with the least fitness cost may occur in vivo.
Mutations giving rise to drug resistance have also been studied on serial samples from treated tuberculosis patients [6, 7] . These studies have documented that mixed populations of resistant and sensitive M. tuberculosis exist in a single clinical sample, and that more than 1 mutation can emerge during treatment. This mixed state of sensitive and resistant alleles, called heteroresistance [8] , was detected in about 20% of sputum samples containing resistant organisms [9, 10] . Although these studies consider heteroresistance to be defined by the presence of both resistant and sensitive alleles in the same sputum, heteroresistance may also describe a mixed infection containing different drug resistance-conferring alleles, which then may be selected for those with the lowest fitness cost in vivo.
Drug-resistant clinical isolates are also often found to have enhanced fitness compared to their apparently isogenic in vitro selected counterparts (at least as measured by in vitro growth rate), which suggests the evolution of unidentified compensatory mutations in vivo [4] . Since most drug resistance-associated alleles impose a fitness cost [4, 11, 12] , compensatory evolution may play an important role in the stable fixation of such mutants within the bacterial population. However, due to the complexity of compensatory mechanisms, very few of them have been elucidated in M. tuberculosis [13] [14] [15] . Previous studies on resistant M. tuberculosis have mainly focused on resistance-conferring mutations, and the potential compensatory changes have usually been neglected [6, 7] .
Recent developments in genome sequencing technologies provide an unprecedented opportunity to study the diversity of populations of microorganisms [16] . Effective statistical approaches to differentiate technical errors from real polymorphisms and high-sequencing coverage enable accurate detection of low-frequency variants in microorganism populations [17, 18] . Deep sequencing of genes from human immunodeficiency virus and hepatitis C virus has begun to reveal patterns of within-host diversity and evolution during infections [18, 19] . A study on a series of mixed-population Escherichia coli samples has uncovered changes in the genetic structure of the population during long-term in vitro evolution [17] . Despite these advances, previous whole-genome sequencing studies of M. tuberculosis have mainly focused on polymorphisms between transmitted MDR and XDR strains after isolating single-colony isolates [20] [21] [22] . A recent study performed wholegenome sequencing on serial sputum samples from an MDR-Tuberculosis patient; however, due to the limitations of analytical methods, very few resistance-conferring mutations were characterized and the evolution of bacterial populations remained unclear [23] .
In the present study, we sequenced the bacterial genomes of serially collected samples from treated tuberculosis patients. By identifying the genetic variations during antibiotic treatment, we aim to further understand the in vivo evolution of resistance associated and potential compensatory mutations.
METHODS

Selection of Patients and Samples
M. tuberculosis sputum samples were collected through routine clinical work and cultured on slopes by local hospitals. After about 4 weeks, culture-positive slopes were sent to Shanghai Municipal Center of Disease Control and Prevention (Shanghai CDC), where the bacteria were harvested to 1 mL 15% glycerol and refrigerated in the specimen bank. Approved by the Ethical Review Committee of Shanghai CDC, we selected the tuberculosis patients with serial samples during the treatment, and strains from the same patient shared identical 16 hyperpolymorphic variable-number tandem repeat (VNTR) patterns [24] .
The drug susceptibility tests (DSTs) were performed by the concentration method. The concentration for each antibiotic was as follows: RIF, 50 μg/mL; INH, 50 μg/mL; SM, 10 μg/mL; EMB, 5 μg/mL.
Genome Sequencing
In the present study, 0.5 mL of each preserved sample (about 50% of the original culture) was spread onto a fresh Lowenstein-Jensen plate. After 4 weeks' culture, all the bacteria colonies were scratched from the plate and the genomic DNA was extracted following the protocol of cetyltrimethylammonium bromide-lysozyme method [25] . A 300-base-pair (bp) paired-end library was constructed for each purified DNA sample following the standard Illumina paired-end protocol with a low-cycle polymerase chain reaction during the fragment enrichment, and sequencing was performed on the Illumina Genome Analyzer platform with 95 or 115 cycles. The sequencing data were submitted to the National Center for Biotechnology Information Sequence Read Archive under the Accession No. SRA050212.1.
Reads Processing
The pipeline that we applied for analyzing bacteria populations was a combination of previously published protocols (see Supplementary Figure 1 ). The FASTQ data were transformed to the Sanger format, followed by the trimming of adaptor and low-quality bases at the 3′ ends by Scythe (https://github.com/ucdavis-bioinformatics/scythe) and Sickle (https://github.com/ucdavis-bioinformatics/sickle), respectively. Reads alignment was performed by Burrows-Wheeler Aligner [26] . To improve the accuracy of mutation calling, we employed 2 reference genomes for this and subsequent processes. One is the standard reference strain, M. tuberculosis H37Rv (GenBank: AL123456) [27] and the other is CCDC5079 (GenBank: CP001641) [28] , a clinical isolate close to our strains. After duplicates marking and local realignment by Genome Analysis ToolKit [29] , the software Samtools [30] was used to convert aligned reads into pileup-formatted files.
To ensure the reliability of subsequent analysis, we first discarded low-quality bases with Phred quality scores lower than 20. Then, we removed 2% of sites with the lowest coverage and loci with coverage higher than twice the average level. Indels, mobile genetic elements, and PE/PPE and PE-PGRS gene families that might cause incorrect read alignment were also excluded.
Distinguishing Sequencing From Real Mutations
For sites with only single mapping result, fixed mutations with frequency of 100% were first identified. For the other loci with heterozygous mapping results, the protocol and parameters for mutation calling, including base error model, likelihood ratio test, and bias filtering were referenced from a published methodology [17] .
Identifying Significant Genomic Changes
The detected frequency for each single-nucleotide polymorphism (SNP) was calculated by a maximum likelihood approach [17] . Considering the minimal sequencing depth included for our analysis, SNPs with frequencies higher than 95% were defined as fixed mutations, while those with frequencies from 5% to 95% were defined as unfixed mutations. For fixed SNPs that were repeatedly detected in all serial samples from the same patient, they were grouped as common fixed mutations that emerged before the sampling intervals. For unfixed SNPs that were only detected by one reference but not by the other, they were excluded as false-positive results caused by reference-specific improper read mapping. The other SNPs, including a few fixed mutations that were only observed in part of the samples and unfixed mutations with varying frequencies, were grouped as characteristic mutations, representing genetic variations during treatment.
To identify significant genomic changes at a given locus between serial samples, the numbers of aligned reads harboring wild and mutated genotype were submitted to the Fisher exact test. The p value was then multiplied by the total number of included bases to gain an E value. A significant genomic change was defined by E value lower than 1.
RESULTS
Patients and Samples
Seven sputum samples from 3 patients (denoted A-C) were collected for analysis (Figure 1 ). Patient A was sampled over a 23-month period during which this subject developed isoniazid monoresistance. This subject had a record indicating poor compliance from the 3rd to the 13th month. Patient B was sampled over an 18-month period during which this subject acquired rifampin resistance in addition to their initial isoniazid and streptomycin resistance. Patient C was a retreatment case and was sampled over an 11-month treatment for MDRTuberculosis and showed no change in their underlying resistance pattern. In each subject, we verified that the initial and subsequent samples shared identical 16-VNTR profiles, indicating they originated from the same clonal population. Different VNTR profiles were observed among different patients, suggesting these 3 cases are epidemiologically unrelated. All these cases were infected by the Beijing family strains [31] , the most dominant M. tuberculosis genotype in Shanghai.
Genome Sequencing
DNA samples were prepared immediately after growing the original sputum sample on Lowenstein-Jensen media to avoid as much as possible enriching for siblings with different growth rates. For each sample we obtained 3.7 to 20.2 million 115 bp or 95 bp single/paired-end reads corresponding to an average sequencing depth ranging from 55-to 269-fold, and these were aligned to the reference genome of M. tuberculosis H37Rv and CCDC5079, respectively. The sequencing coverage across the reference genomes was approximately 99%. To ensure the reliability of our results, we discarded 2% of loci with the lowest sequencing depth and loci with depth higher than twice the average level. Indels, mobile elements, and the PE/PPE-PGRS gene families, which may result in inaccurate identification of mutations, were also excluded. In total, bases covering about 90% of the reference genomes were included for subsequent analysis (see Supplementary Table 1) .
Intrapatient Population Diversity
Standard tuberculosis treatment for drug-susceptible disease usually lasts for 6 months, but for MDR-Tuberculosis treatment, durations are much longer, typically 18-24 months. We hypothesized that during this prolonged treatment, M. tuberculosis might generate and accumulate adaptive mutations that contribute to fitness under antibiotic stress. To characterize genetic variations that evolved within our samples, we analyzed SNPs and their corresponding frequencies in each longitudinal population. After aligning reads to the reference genomes, we employed a likelihood ratio test and a bias filter to differentiate real SNPs from technical errors [17] . Then, by comparing the SNPs between serial samples, we identified characteristic mutations that evolved during treatment.
With frequency threshold at 5%, this analysis yielded 8-41 characteristic SNPs in each sample (Figure 2A , or see Supplementary Table 2 ). These included 6-34 "private" SNPs that were only found in 1 sample and were not found in subsequent or prior samples, suggesting microheterogeneity in the population sampled in the sputum at each time point. Among the total SNPs in subsequent isolates, 82.7% were found at frequencies lower than 20% (Figure 2B-D) . Sixteen SNPs, including 6 mutations known to be associated with drug resistance, were found at frequencies higher than 50%. These SNPs were mainly (14/16) identified in the second or third sample and were consistent with the emergence of new mutations in these treated populations as a result of selection of mutations conferring drug resistance and other SNPs of adaptive potential.
Evolution of Drug Resistance-Associated Mutations
We observed heteroresistance in all 3 patients with multiple mutations associated with drug resistance to isoniazid, rifampin, and ethionamide, respectively. To understand the evolution of drug resistance, we examined the detailed population structure of these resistant bacteria over time.
In patient A, the initially untreated population was sensitive to all drugs ( Figure 3A) . After 19 months of treatment, the clinical laboratory using standard drug susceptibility testing identified isoniazid resistance. Our sequencing results at this time point indicated that the isoniazid resistance was conferred by as many as 4 independent resistance mutations: 3 in the katG gene, including V1A (5.1%), D94N (56.8%), and S315R (19.5%); and a fourth one in the promoter region of inhA, C-15T (20.0%). Because the genomic distance between these mutations were longer than the sequencing reads, mutated bases at 1 locus were not likely to bias the detection frequency of the other mutations. The total frequency of these 4 resistance mutations was very close to 100%, suggesting that the treatment of patient A had successfully eliminated sensitive bacteria and selected for a spectrum of resistant mutants that simultaneously existed within this subject. Five months later, the inhA C-15T promoter mutation had become undetectable and the frequencies of katG S315R and V1A had decreased to 0.6% and 0.8%, respectively. In contrast, the katG D94N allele had expanded to 94.2% of the reads, suggesting this mutant had superior fitness compared to the other 3. Because of the high sequencing depth of sample a3, which had about 300-fold coverage on the katG gene, 2 other mutations at katG G125V (2.6%) and L611R (1.6%) were also detected as candidate mutants that may also have caused isoniazid resistance.
For patient B, an initial sputum sample was not available, but at the 18th month, a mutation in rpoB (L533P) was uniformly present in the sample ( Figure 3B ). However, drug-susceptibility testing indicated the sample remained rifampicin susceptible. Consistent with this, the rpoB L533P has been previously reported to confer only low-level rifampin resistance [32] . This subject remained on first-line therapy for another 18 months after which sequence analysis revealed that the rpoB L533P allele had been replaced primarily by rpoB H526Y (76.3%), an allele associated with high-level rifampicin resistance that confers a relatively low fitness cost [4] .
In the retreatment case of patient C, unfixed mutations ethA L35R (75.7%) and A341E (16.4%) were simultaneously detected in the initial sample, suggesting acquired ethionamide resistance during the previous treatment. After an 11-month treatment, both mutations remained in the sample with frequencies at 88.0% and 11.9%, respectively ( Figure 3C ). Unlike the dynamic evolution of newly acquired resistance in these patients, the other resistanceconferring mutations were stable fixed SNPs (Table 1) . These included known mutations at katG S315T, rpoB S531L, and rpsL K43R, all of which were fixed prior to our initial sample.
Potential Adaptive Mutations
There were mutations in the bacterial populations that increased in frequency during treatment, particularly in the case of patient C, with stable drug-resistance mutations. These results suggest that adaptive evolution continues to occur in alleles not related to drug resistance. We hypothesized that mutations with significant changes in frequencies might be relevant to the population's fitness. To identify these significant events, we employed the Fisher exact test to compare the characteristic SNPs in each serial sample. With E value lower than 1, our process yielded 19 significantly changed mutations, including 15 nonsynonymous, 2 intergenic, and 2 synonymous mutations that emerged through genetic hitchhiking ( Table 2) .
As expected, this analysis identified the emergence of the 3 drug resistance-associated mutations (katG D94N, S315R, and inhA C-15T) in patient A and 2 rpoB mutations (H526Y and L533P) in patient B as significant events. In addition to these, there were 11 nonsynonymous mutations that showed significant changes. Seven of these were found in patient C and 5 had risen to frequencies over 80%. It was surprising to find that the bacterial populations from patient C were so variable compared with their stable resistance phenotype and corresponding mutations conferring drug resistance. Given that no significant mutation was detected in population a1 and the high prevalence of resistant mutants in the other 6 populations, most of these nonresistance-associated mutations occurred with or after the emergence of resistance-conferring mutations. Therefore, these mutations suggest that the M. tuberculosis population within the host may be undergoing adaptive evolution to improve the fitness of the bacteria.
Although the relevance between these potential adaptive mutations and drug resistance was not clear, 7 of them showed similarity to genes related to cell wall biosynthesis or membrane proteins. One selected mutation was observed in fadD32, an essential gene in mycolic acid biosynthesis [33, 34] . As the fadD32 E444G emerged after the selection of katG D94N, and the mechanism of isoniazid is to inhibit mycolic acid synthesis, this SNP might be a compensatory mutation that improved the fitness of population a3.
DISCUSSION
Using whole-genome sequencing, we have studied the withinhost population diversity and evolution of M. tuberculosis during treatment for active disease. In all 7 samples, we found a surprising level of genetic diversity to adapt to antibiotic stress that as many as 4 to 5 different resistant mutants were detected in a single sputum sample. These data suggest that heteroresistance might be a common feature of M. tuberculosis 
Unfixed mutations are highlighted in bold.
Abbreviations: E, ethambutol; H, isoniazid; R, rifampin; S, streptomycin; Th, ethionamide; Z, pyrazinamide. population with newly acquired resistance. Although multiple discrete resistant mutants transiently coexist in the same population, ultimately only a single type of mutant was selected. The data from patient B imply that the final selection for resistance mutation might be associated with their resistance level and fitness cost. As we saw, during the 18-month treatment, an initially fixed mutation rpoB L533P that reportedly associated with low-level rifampin resistance [35, 36] , was outcompeted by another candidate that conferred high-level resistance and relatively low fitness cost [4, 5, 12, 32] . The similar phenomenon was also reported on streptomycin resistance where the high-cost mutations rpsL K88T or K88R was replaced by rpsL K43R, a highly resistant mutation with no fitness cost [6, 7] . The mechanism of selecting high-resistant and low-cost mutants in vivo and subsequent transmission may contribute to the high prevalence of these drug-resistant mutants in reports from clinical isolates [5] . The in vivo selection of low-cost mutations may occur through competition between different populations of siblings with different drug-resistant mutations. The competition between beneficial mutations within a clonal population, or clonal interference, has been studied in asexual populations like viruses [37] , E. coli [38] , and yeast [39] , but has been only rarely reported in M. tuberculosis. Clonal interference is usually observed in populations with effective population size (N e ) larger than 2 × 10 4 [38] . Though the in vivo N e of M. tuberculosis is not readily measurable, and may differ with patients depending on the extent of disease, the density of M. tuberculosis in sputum may reach 10 5 -10 6 colony-forming units (CFU)/mL [40, 41] . Estimates from nonhuman primate model also reported bacterial burden at about 1.4 × 10 5 CFU per cm 3 of granuloma [42] , or 10 7 CFU per animal [43] . Therefore, we speculate that the heterozygous community of M. tuberculosis has sufficient N e to allow for clonal interference during active infection. It is worthwhile to point out that the heterogeneity of M. tuberculosis was usually found in different lesions [44, 45] , which meant the dynamics of drug-resistant mutants in our study may also be affected by biased sampling from multiple lesions. Under current design, it is difficult to quantitate the impact of sampling bias or other uncertainties such as genetic drift. Therefore, more evidence is required to support the hypothesis of clonal interference in M. tuberculosis. Mathematic model predicts that as the population size increases, clonal interference results in greater fitness improvement [46] . In case of M. tuberculosis, it means that low-cost drug-resistant mutations are more likely to be selected from large populations. This conclusion highlights the importance of sensitive diagnostic tests, which allow for early medical intervention when the bacterial burden and diversity remains low. Nowadays, novel diagnostic test such as Xpert M. tuberculosis/RIF have decreased the limit of detection to 131 CFU/ mL [47] , about 100 times more sensitive than conventional sputum smear microscopy. Strategic application of these sensitive diagnostic tools may have the ability to minimize or prevent tuberculosis cases with acquired drug resistance.
Previous studies indicate that resistant strains sometimes acquire additional mutations outside of the affected gene to improve their fitness through compensatory evolution [4, 48] . However, except for mutations in the ahpC promoter, which may compensate for the inactivation of katG [14] , very few compensatory mutations have been identified. Recently, compensatory mutations for restoring fitness in rifampin-resistant strains with lesions in rpoB were identified in the genes rpoA and rpoC [15] . One of the high-probability compensatory mutations (HCMs) rpoC V483G was also detected in our samples from patient C. Because this mutation was fixed before our sampling intervals, the other newly evolved mutations in patient C may act as compensatory mutations for other resistant phenotypes. Considering the different mechanisms of antibiotics, it is possible that there are many compensatory changes in different genes to compensate for drug resistanceassociated fitness costs [49] . The dynamic heteroresistance in our samples indicate that before the stabilization of drug resistant mutations, the compensatory mutations are being rapidly sampled and the solutions may be very diverse. This might explain the failure to confirm possible compensatory mutations of KZN MDR/XDR strains in other strains with drug resistance [50] . Despite the high diverseness of compensatory mutations, the mutations found in our study and in KZN strains shared several similarities such as cell wall synthesis and the metabolism of mycolic acids [50] . These diverse mutations in certain pathways such as cell wall synthesis are not unexpected given the number of agents used that interfere with this pathway, and any of them might act as compensatory mutations. These mutations will need to be studied in vitro in genetically defined backgrounds to conclusively show they are genuinely compensatory.
By studying the genetic diversity and dynamics of intrapatient M. tuberculosis populations, we have just started to understand the battle between antibiotics and M. tuberculosis. Clonal interference between different resistant mutations may play a major role in the selection of low-cost mutations, as well as in the development of compensatory changes. These results suggest that the bacillus has a surprisingly high rate of generating genetic diversity and can efficiently sample many different solutions to the challenge of surviving chemotherapy. A better understanding of these dynamics, and their mechanisms, may allow for the development of treatment strategies to avoid the generation and stable fixation of drug resistance in M. tuberculosis strains. data provided by the author that are published to benefit the reader. The posted materials are not copyedited. The contents of all supplementary data are the sole responsibility of the authors. Questions or messages regarding errors should be addressed to the author.
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